Dare Bioscience, Inc. (DARE): Nasdaq/NYSE listing notice — Dare Bioscience receives Nasdaq deficiency notice for stock price below $1.00

Dare Bioscience, Inc.

Nasdaq notified Dare on Dec 16, 2022 that its common stock closed below $1.00 for 30 consecutive business days.
The company has 180 calendar days, until June 14, 2023, to regain compliance with the minimum bid price rule.
Compliance can be achieved if closing bid price is at least $1.00 for 10 consecutive business days.
If not compliant by June 14, 2023, Dare may be eligible for an additional 180-day period subject to meeting other standards.
Failure to regain compliance could result in delisting from Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dare Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 16, 2022, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq list

View on SEC.gov

Browse all listing & compliance notices →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-035781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.